Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$3.36 USD
+0.11 (3.38%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $3.39 +0.03 (0.89%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Tempest Therapeutics, Inc. [TPST]
Reports for Purchase
Showing records 21 - 31 ( 31 total )
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Clinical Strategy Execution Continues; First Clinical Update Coming at ASCO; Target Adjusted to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR Preclinical Updates Highlight Differentiation Across Two Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Ready to Make Waves in 2022; First Clinical Data Presentation Planned for ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Who Said You Can?t Find Shelter in a Tempest?; Steady Pipeline Progress in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TPST-1495 Continues Its Journey; First Patient Dosed in Phase 1a/1b Study in Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC Further Highlights TPST-1495 Differentiation
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Pipeline Under Control; Holding Hands With Roche for TPST-1120
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TPST-1120 Pushes Forward; First Patient Dosed in Phase 1b/2 Study in HCC Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Tempest Firing On All Cylinders; Making Strides In Three Lead Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tempest Primed to Make Waves in Targeted Oncology; Initiating at Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J